Timolol 0.5% Eye Drops 5 ml

Timolol

Prescription ophthalmic medicine

Topical beta\u2011blocker eye drops (glaucoma / ocular hypertension)

Marketing authorisation holder in UK: FDC International Ltd — PL 15872/0002 for Timolol 0.5% Eye Drops. :contentReference[oaicite:27]{index=27}

Marketing authorisation holder in UK: FDC International Ltd — PL 15872/0002 for Timolol 0.5% Eye Drops. :contentReference[oaicite:27]{index=27}

Topical beta\u2011blocker eye drops (glaucoma / ocular hypertension)

Description

Timolol 0.5% eye drops contain timolol maleate, a non‑selective beta‑adrenergic receptor blocking agent, formulated as a sterile, isotonic, buffered aqueous solution for topical ocular use. It is used to reduce elevated intra‑ocular pressure (IOP) in conditions such as ocular hypertension and chronic open-angle glaucoma (including some secondary glaucomas), by decreasing production of aqueous humour. :contentReference[oaicite:2]{index=2}

Bnefits

Reduces elevated intra‑ocular pressure — helps in management of ocular hypertension and glaucoma. :contentReference[oaicite:3]{index=3}
Topical administration — directly targets the eye with fewer systemic effects compared to oral beta‑blockers. :contentReference[oaicite:4]{index=4}
Once- or twice-daily dosing — convenient for long-term therapy. :contentReference[oaicite:5]{index=5}
Solution is clear, sterile, and suitable for ophthalmic use. :contentReference[oaicite:6]{index=6}

Indications

Ocular hypertension
Chronic open-angle glaucoma (including aphakic patients)
Certain cases of secondary glaucoma where pressure lowering with beta‑blockers is appropriate :contentReference[oaicite:7]{index=7}

Composition

Active ingredient: Timolol maleate, equivalent to 5.0 mg timolol per mL (0.5% w/v) :contentReference[oaicite:8]{index=8}
Excipients with known effect: Benzalkonium chloride 0.10 mg/mL (preservative), disodium phosphate dodecahydrate, sodium dihydrogen phosphate dihydrate, sodium chloride, sodium hydroxide, water for injections :contentReference[oaicite:9]{index=9}

Formulation

Sterile, isotonic, buffered aqueous solution for ophthalmic use, clear to pale yellow, free of visible particulates. :contentReference[oaicite:10]{index=10}

Packaging

5 mL sterile dropper bottle (LDPE) with dropper nozzle and tamper‑evident cap. :contentReference[oaicite:11]{index=11}

Usage

Wash your hands before use. :contentReference[oaicite:12]{index=12}
Remove contact lenses before instillation; wait at least 15 minutes after drops before reinserting soft contact lenses. :contentReference[oaicite:13]{index=13}
Tilt your head back, gently pull down lower eyelid, instill one drop into the affected eye(s). :contentReference[oaicite:14]{index=14}
If prescribed twice daily, instill once in the morning and once in the evening about 12 hours apart. :contentReference[oaicite:15]{index=15}
Avoid touching the dropper tip against the eye, eyelid or skin to prevent contamination. :contentReference[oaicite:16]{index=16}
If wearing contact lenses, remove before use and wait at least 15 minutes before reinserting. :contentReference[oaicite:17]{index=17}

Contraindications

Cardiogenic shock, overt cardiac failure, second or third degree atrioventricular block (unless paced), sinus bradycardia, sick sinus syndrome/sino‑atrial block. :contentReference[oaicite:20]{index=20}
Reactive airway disease including bronchial asthma or history of asthma; severe chronic obstructive pulmonary disease (COPD). :contentReference[oaicite:21]{index=21}
Hypersensitivity to timolol or any excipient (e.g. benzalkonium chloride) or to other beta‑blocking agents. :contentReference[oaicite:22]{index=22}

Adverse Effects

Ocular: transient burning, stinging, itching, tearing, redness, foreign body sensation, conjunctivitis, blepharitis, keratitis, dry eyes, decreased corneal sensitivity, blurred vision, visual disturbances, diplopia, ptosis, rarely corneal erosion or rare corneal calcification (in compromised corneas). :contentReference[oaicite:23]{index=23}
Systemic (due to absorption): bradycardia, cardiac arrhythmias, hypotension, exacerbation of cardiac failure, bronchospasm (especially in patients with asthma/COPD), respiratory issues, dyspnoea, fatigue; also potential effects on heart, vascular, metabolic, neurological, gastrointestinal, skin, and other systems as described in the SmPC. :contentReference[oaicite:24]{index=24}

Storage Conditions

Do not store above 25 °C; store bottle in the outer carton to protect from light. :contentReference[oaicite:25]{index=25}
Discard solution 28 days after opening the bottle. :contentReference[oaicite:26]{index=26}

Duration

Long-term as directed by ophthalmologist \u2014 typically chronic therapy for glaucoma / ocular hypertension; re-evaluate IOP approx. 4 weeks after starting. :contentReference[oaicite:18]{index=18}

Onset

Initial reduction in intra\u2011ocular pressure may begin within about 30 minutes; maximal effect typically achieved 1\u20132 hours after instillation. :contentReference[oaicite:19]{index=19}